Correlation Between Virpax Pharmaceuticals and FIRST NIAGARA

Can any of the company-specific risk be diversified away by investing in both Virpax Pharmaceuticals and FIRST NIAGARA at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virpax Pharmaceuticals and FIRST NIAGARA into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virpax Pharmaceuticals and FIRST NIAGARA FINL, you can compare the effects of market volatilities on Virpax Pharmaceuticals and FIRST NIAGARA and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virpax Pharmaceuticals with a short position of FIRST NIAGARA. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virpax Pharmaceuticals and FIRST NIAGARA.

Diversification Opportunities for Virpax Pharmaceuticals and FIRST NIAGARA

-0.48

Correlation Coefficient

Virpax Pharmaceuticals  FIRST NIAGARA

Very good diversification

The 3 months correlation between Virpax and FIRST is -0.48. Overlapping area represents the amount of risk that can be diversified away by holding Virpax Pharmaceuticals and FIRST NIAGARA FINL in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on FIRST NIAGARA FINL and Virpax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virpax Pharmaceuticals are associated (or correlated) with FIRST NIAGARA. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of FIRST NIAGARA FINL has no effect on the direction of Virpax Pharmaceuticals i.e., Virpax Pharmaceuticals and FIRST NIAGARA go up and down completely randomly.

Pair Corralation between Virpax Pharmaceuticals and FIRST NIAGARA

Given the investment horizon of 90 days Virpax Pharmaceuticals is expected to under-perform the FIRST NIAGARA. In addition to that, Virpax Pharmaceuticals is 66.84 times more volatile than FIRST NIAGARA FINL. It trades about -0.49 of its total potential returns per unit of risk. FIRST NIAGARA FINL is currently generating about 0.05 per unit of volatility. If you would invest  1,304  in FIRST NIAGARA FINL on February 22, 2025 and sell it today you would earn a total of  5.00  from holding FIRST NIAGARA FINL or generate 0.38% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	92.5%
Values	Daily Returns

Virpax Pharmaceuticals  vs.  FIRST NIAGARA FINL

Virpax Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

FIRST NIAGARA FINL

Risk-Adjusted Performance

Insignificant

Over the last 90 days FIRST NIAGARA FINL has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, FIRST NIAGARA is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Virpax Pharmaceuticals and FIRST NIAGARA

The main advantage of trading using opposite Virpax Pharmaceuticals and FIRST NIAGARA positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virpax Pharmaceuticals position performs unexpectedly, FIRST NIAGARA can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FIRST NIAGARA will offset losses from the drop in FIRST NIAGARA's long position.

The idea behind Virpax Pharmaceuticals and FIRST NIAGARA FINL pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.